Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Runben Biotechnology Co's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 17.37%.
As of today (2026-07-31), Runben Biotechnology Co's WACC % is 10.68%. Runben Biotechnology Co's ROC % is 29.32% (calculated using TTM income statement data).
Runben Biotechnology Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Runben Biotechnology Co (SHSE:603193) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Runben Biotechnology Co's WACC % is 10.68%. Runben Biotechnology Co's ROC % is 29.32% (calculated using TTM income statement data).
Runben Biotechnology Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Mar. 2026) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Runben Biotechnology Co (SHSE:603193) has a ROC % of 17.37% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Runben Biotechnology Co and its competitors.
Is Runben Biotechnology Co's ROC % too high?
Runben Biotechnology Co's current ROC % is 17.37%. The Consumer Packaged Goods industry median ROC % is 5.22. Runben Biotechnology Co's value of 17.37% is 232.8% above this industry median. Overall, Runben Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Runben Biotechnology Co's ROC % compare to PG and CL?
Runben Biotechnology Co's ROC % of 17.37% can be compared against companies in the Consumer Packaged Goods industry. The industry median ROC % is 5.22. Runben Biotechnology Co's value of 17.37% is 232.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Consumer Packaged Goods company?
The median ROC % among Consumer Packaged Goods companies is 5.22, based on 1,950 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Runben Biotechnology Co's current ROC % of 17.37% is 232.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Runben Biotechnology Co and its competitors. For the Consumer Packaged Goods industry, the median ROC % is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Runben Biotechnology Co's current ROC % is 17.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Runben Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Runben Biotechnology Co (SHSE:603193) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.24, compared to a current price of ¥21.96 — trading 22.2% below its estimated fair value. The current ROC % is 17.37% and 232.8% above the Consumer Packaged Goods industry median of 5.22. Runben Biotechnology Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Runben Biotechnology Co (SHSE:603193), the current ROC % is 17.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Runben Biotechnology Co (SHSE:603193) Overvalued in 2026?
Based on GuruFocus' analysis, Runben Biotechnology Co stock appears to be undervalued.
The current stock price of ¥21.96 is trading 22.2% below its estimated GF Value™ of ¥28.24.
GuruFocus considers Runben Biotechnology Co to be Modestly Undervalued.
Key valuation signals for SHSE:603193:
ROC %: 17.37%
GF Value™: ¥28.24 vs. price of ¥21.96 (22.2% below fair value)
Industry Position: 232.8% above the Consumer Packaged Goods median
No single metric tells the full story. See the SHSE:603193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603193 has been successfully added to your 
